Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie RC48-ADC pro léčbu lokálně pokročilého nebo metastatického karcinomu prsu s nízkou expresí HER2

20. září 2026 aktualizováno: RemeGen Co., Ltd.

Randomizovaná, kontrolovaná, multicentrická klinická studie fáze III hodnotící účinnost a bezpečnost RC48-ADC pro léčbu lokálně pokročilého nebo metastatického karcinomu prsu s nízkou expresí HER2

This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ,previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Detailní popis

This study is a multi-center, randomized, open, parallel control to evaluate the effectiveness and safety of Phase III clinical trials of the efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody-Monomethyl auristatin E (MMAE) conjugate for the treatment of locally advanced or metastatic breast cancer the study.The low expression of HER2 is defined as: the immunohistochemistry (IHC) confirmed by the central laboratory detects the expression of HER2 protein as IHC 2+ and the fluorescence in situ hybridization (FISH) detection has no amplification.

Typ studie

Intervenční

Zápis (Odhadovaný)

366

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Binghe Xu, M.D.
  • Telefonní číslo: 010-87788826
  • E-mail: bhxu@hotmail.com

Studijní místa

    • Beijing Municipality
      • Beijing, Beijing Municipality, Čína, 100021
        • Nábor
        • Oncology Hospital, Chinese Academy of Medical Sciences
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 70 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Voluntarily agree to participate in the study and sign the informed consent;
  • Subjects aged 18-70 years (including 18 years and 70 years) and not reaching the 71st birthday were all considered to be ≤70 years old;
  • Expected survival ≥12 weeks;
  • Eastern Cooperative Oncology Group(ECOG) physical condition 0 or 1;
  • For female subjects of child-bearing age women agreed to study during treatment and experimental subjects within 6 months after the end of the treatment period using an approved by the medical contraception (e.g. intrauterine device, the pill or condoms), before the study drug delivery within 7 days of pregnancy blood test must be negative (sterilization surgery or age 60 or more subjects can choose no pregnancy blood test), and must be an lactation. For male subjects: should be sterilized surgically, or agree to use a medically approved contraceptive method during the study period and for 6 months after the end of the treatment period. Control subjects after the end of the treatment period according to the choice of control drugs to determine the length of contraception.
  • Able to understand the study requirements and be willing and able to follow the study and follow-up procedures.
  • Bone marrow function:

hemoglobin ≥9g/dL; absolute neutrophil count ≥1.5×109/L; white blood cell count ≥3.0×109/L platelet ≥100 ×109/L;

  • Liver function (according to the normal value of the clinical trial center) :

serum total bilirubin ≤1.5 times the upper limit of normal value (ULN); alanine aminotransferase (ALT), aspartate aminotransferase(AST) and Alkaline phosphatase(ALP) were ≤2.5 × ULN in the absence of liver metastasis, and ALT, AST and Alkaline phosphatase(ALP) were ≤5 × ULN in the presence of liver metastasis

  • Renal function (according to the normal value of the clinical trial center) :

serum creatinine ≤1.5×ULN, or calculated by Cockcroft-Gault formula, the creatinine clearance rate (CrCl) ≥60 mL/min;

  • Cardiac function:

American New York college of cardiology (NYHA) grade < 3; left ventricular ejection fraction ≥50%;

  • Breast cancer subjects diagnosed by histology and / or cytology are currently at a locally advanced or metastatic stage and cannot be radically removed;
  • The low expression of HER2 confirmed by the IHC and FISH results of the central laboratory (defined as: IHC 2+ and no amplification of FISH); the subject can provide a specimen of the primary or metastatic tumor site (paraffin wax) for HER2 detection Block, paraffin-embedded section or fresh tissue section can be used);
  • Previous use of anthracycline drugs;
  • Received 1 or 2 systemic chemotherapy treatments after relapse / metastasis. Subjects who relapsed during adjuvant chemotherapy or within 12 months after the end of adjuvant chemotherapy were considered to have failed first-line chemotherapy after relapse / metastasis.
  • Hormone receptors are negative or positive. Hormone receptor-positive subjects need to progress after receiving endocrine therapy after relapse / metastasis or relapse after less than 2 years. Patients who are not suitable for endocrine therapy can be included in this study after undergoing chemotherapy treatment (first-line or second-line);
  • The imaging evidence confirmed by the investigator that the tumor disease progressed during or after the most recent treatment is required;
  • There has been no diagnosis of HER2 positive (HER2 IHC 3+ or FISH amplification)
  • Have not used drugs targeting HER2 (including antibodies, small molecule Tyrosine kinase inhibitor(TKIs) and antibody drug conjugates).
  • According to the RECIST 1.1 standard, there is at least one measurable lesion.

Exclusion Criteria:

  • Received chemotherapy within 4 weeks before the start of study administration (treatment with nitrosourea and mitomycin C within 6 weeks, oral fluorouracil within 2 weeks), radiotherapy (palliative for bone metastases Local radiotherapy is within 2 weeks before study administration), immunotherapy; received endocrine therapy for breast cancer within 2 weeks before study administration;
  • The research drug was used within 4 weeks before the start of study administration;
  • Have undergone major surgery within 4 weeks before the start of study administration;
  • Have received a live vaccine within 4 weeks before the start of study administration or plan to receive any vaccine during the study period;
  • Serious cardiovascular and cerebrovascular events occurred within 12 months, including but not limited to unstable angina, myocardial infarction, cerebral hemorrhage, and cerebral infarction (except for asymptomatic and untreated lacunar infarction);
  • Those who are suffering from heart disease are not suitable for enrollment, including but not limited to arrhythmia and heart failure requiring medical treatment or accompanied by symptoms;
  • There are other lung diseases requiring treatment or serious, including but not limited to active pulmonary tuberculosis, interstitial lung disease, etc ;
  • Suffering from active infection requiring systemic treatment;
  • Have active autoimmune diseases (such as the use of corticosteroids or immunosuppressive drugs, etc.) that require systemic treatment within the past 2 years, allowing related alternative treatments (such as thyroxine, insulin, or the physiology of adrenal or pituitary insufficiency Corticosteroid replacement therapy);
  • The toxicity of the previous anti-tumor therapy has not been restored to the 0 to 1 level defined by CTCAE version 5.0, of which the neurotoxicity has not been restored to 0; except for hair loss, pigmentation or other researches that do not increase the risk of medication Happening;
  • Have a clear past or current history of neurological or mental disorders, including epilepsy or dementia;
  • According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the clinical study;
  • Positive HIV test results; patients with active hepatitis B or C (HBsAg positive and hepatitis B virus(HBV) DNA titers above the upper limit of normal; Hepatitis C Virus Antibody(HCVAb) positive hepatitis C virus (HCV) RNA titers above the upper limit of normal);
  • There is a third interstitial fluid that cannot be controlled by drainage or other methods (including a large amount of pleural effusion or ascites);
  • Known hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or similar drugs;
  • Subjects who are not suitable for using any of the alternative control drugs;
  • The presence of brain metastases and / or cancerous meningitis;
  • Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured);
  • Subjects who are estimated to be inadequate for patients to participate in this clinical study or other factors that the investigator believes are inappropriate to participate in this study;

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: RC48-ADC

RC48-ADC common name:Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection Dosage form:Lyophilized powder injection specification:60 mg / piece Medication plan:Every 2 weeks Expiration date:18 months HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.

RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks

Ostatní jména:
  • RC48
Aktivní komparátor: Physician's Choice

Physician's Choice:

HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.

Physician's choice from the following options:

Paclitaxel Injection Docetaxel Injection Vinorelbine Tartrate Injection Capecitabine Tablets

Administered according to label, as one option for Physician's Choice (determined before randomization)

Ostatní jména:
  • Taxol

Administered according to label, as one option for Physician's Choice (determined before randomization)

Ostatní jména:
  • Taxotere

Administered according to label, as one option for Physician's Choice (determined before randomization)

Ostatní jména:
  • Navelbine

Administered according to label, as one option for Physician's Choice (determined before randomization)

Ostatní jména:
  • Xeloda

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Progression-free survival (PFS), evaluated by an independent efficacy evaluation committee
Časové okno: within approximately 3 years

Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.

within approximately 3 years

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Progression-free survival (PFS), evaluated by the investigator
Časové okno: within approximately 3 years

Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.

within approximately 3 years
Objective remission rate (ORR)
Časové okno: within approximately 3 years

The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed).

within approximately 3 years
Duration of relief (DOR)
Časové okno: within approximately 3 years

DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death

within approximately 3 years
Disease control rate (DCR)
Časové okno: within approximately 3 years

Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study.

within approximately 3 years
Tumor progression time (TTP)
Časové okno: within approximately 3 years

Time to disease progression (TTP) refers to the time from the random date to the first disease progression (calculated by the event that occurred first). Disease progression will be evaluated by the investigator according to the RECIST 1.1 standard (investigator and Independent Review Committee(IRC) evaluation).

within approximately 3 years
Overall survival (OS)
Časové okno: within approximately 3 years

Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject.

within approximately 3 years

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Vrchní vyšetřovatel: Yu Jiang, West China Hospital
  • Vrchní vyšetřovatel: Binghe Xu, Oncology Hospital, Chinese Academy of Medical Sciences
  • Vrchní vyšetřovatel: Wei Li, Jilin University First Hospital
  • Vrchní vyšetřovatel: Xiaojia Wang, Zhejiang Cancer Hospital
  • Vrchní vyšetřovatel: Ying Wang, Sun Yat-sen University Cancer Prevention and Control Center
  • Vrchní vyšetřovatel: Ning Liao, Guangdong Provincial People's Hospital
  • Vrchní vyšetřovatel: Haibo Wang, Qingdao University Hospital
  • Vrchní vyšetřovatel: Quchang Ouyang, Hunan Cancer Hospital
  • Vrchní vyšetřovatel: Yueyin Pan, Anhui Provincial Hospital
  • Vrchní vyšetřovatel: Yingying Du, The First Affiliated Hospital of Anhui Medical University
  • Vrchní vyšetřovatel: Jin Yang, The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
  • Vrchní vyšetřovatel: Xiuwen Wang, Qilu Hospital of Shandong University
  • Vrchní vyšetřovatel: Huihua Xiong, Tongji Hospital
  • Vrchní vyšetřovatel: Xinhong Wu, Hubei Cancer Hospital
  • Vrchní vyšetřovatel: Weimin Xie, Cancer Hospital Affiliated to Guangxi Medical University
  • Vrchní vyšetřovatel: Xin Zhou, Chongqing University Cancer Hospital
  • Vrchní vyšetřovatel: Li Ran, Cancer Hospital of Guizhou Province
  • Vrchní vyšetřovatel: Yu Wang, Shanxi Province Cancer Hospital
  • Vrchní vyšetřovatel: Jinnan Gao, Bethune Hospital of Shanxi Province
  • Vrchní vyšetřovatel: Jingfen Wang, Linyi Cancer Hospital
  • Vrchní vyšetřovatel: Xianhe Xie, First Affiliated Hospital of Fujian Medical University
  • Vrchní vyšetřovatel: Ru Zeng, The First Affiliated Hospital of Xiamen University
  • Vrchní vyšetřovatel: Airong Wang, Weihai Municipal Hospital
  • Vrchní vyšetřovatel: Zhengqiu Zhu, The Affiliated Hospital of Xuzhou Medical University
  • Vrchní vyšetřovatel: Sanyuan Sun, Xuzhou Central Hospital
  • Vrchní vyšetřovatel: Qingshan Li, Affiliated Hospital of Chengde Medical College
  • Vrchní vyšetřovatel: Aimin Zang, Affiliated Hospital of Hebei University
  • Vrchní vyšetřovatel: Liuzhong Yang, The First Affiliated Hospital of Xinxiang Medical College
  • Vrchní vyšetřovatel: Meili Sun, Jinan Central Hospital
  • Vrchní vyšetřovatel: Liang Li, Zibo Central Hospital
  • Vrchní vyšetřovatel: Guohua Yu, Weifang People's Hospital
  • Vrchní vyšetřovatel: Xujuan Wang, Neijiang Second People's Hospital
  • Vrchní vyšetřovatel: Ying Wang, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • Vrchní vyšetřovatel: Ying Cheng, Jilin Provincial Tumor Hospital
  • Vrchní vyšetřovatel: Jifeng Feng, Jiangsu Cancer Institute & Hospital
  • Vrchní vyšetřovatel: Tao Sun, Liaoning Cancer Hospital & Institute
  • Vrchní vyšetřovatel: Yuee Teng, First Hospital of China Medical University
  • Vrchní vyšetřovatel: Shu Wang, Peking University People's Hospital
  • Vrchní vyšetřovatel: Min Yan, Henan Cancer Hospital
  • Vrchní vyšetřovatel: Changlu Hu, Anhui Provincial Cancer Hospital
  • Vrchní vyšetřovatel: Zhongsheng Tong, Tianjin Cancer Hospital Airport Hospital
  • Vrchní vyšetřovatel: Lihua Song, Shandong Cancer Hospital and Institute
  • Vrchní vyšetřovatel: Yunjiang Liu, Hebei Medical University Fourth Hospital
  • Vrchní vyšetřovatel: Jing Cheng, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • Vrchní vyšetřovatel: Peng Shen, First Affiliated Hospital of Zhejiang University
  • Vrchní vyšetřovatel: Liangming Zhang, Yantai Yuhuangding Hospital

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

29. září 2020

Primární dokončení (Odhadovaný)

31. prosince 2027

Dokončení studie (Odhadovaný)

31. prosince 2027

Termíny zápisu do studia

První předloženo

30. dubna 2020

První předloženo, které splnilo kritéria kontroly kvality

19. května 2020

První zveřejněno (Aktuální)

22. května 2020

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

23. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

20. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .